Immunic, Inc. (IMUX) News

Immunic, Inc. (IMUX)

Today's Latest Price: $12.27 USD

0.42 (-3.31%)

Updated Jul 10 4:00pm

Add IMUX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

Filter IMUX News Items

IMUX News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest IMUX News From Around the Web

Below are the latest news stories about Immunic Inc that investors may wish to consider to help them evaluate IMUX as an investment opportunity.

3 “Strong Buy” Micro-Cap Stocks That Offer Attractive Returns

If you are looking to hit a home run in the stock market, the NASDAQ Composite is a good place to start. The index is home to surging technology, internet, and biotech stocks. Despite the adverse effects from COVID-19, the index is up 25% over the past year, and recently hit a new all-time high. Now comes the hard part. How are investors supposed to determine which stocks are poised to take off? Will the current winners continue climbing, or will new high-flyers emerge? Finding the next big one is challenging to say the least. On top of this, there are numerous and sometimes conflicting investing strategies to consider. Bearing this in mind, Wall Street analysts can provide some inspiration. The experts possess extensive knowledge about the stocks they cover, and offer insights on com...

Yahoo | July 5, 2020

ImmunoGen (IMGN) Investor Presentation - Slideshow

The following slide deck was published by Immunic, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | June 24, 2020

Immunic joins Russell 3000 Index

Immunic (IMUX) is set to join the broad-market Russell 3000 Index, effective after the US market opens on June 29....

Seeking Alpha | June 22, 2020

Immunic, Inc. to Join Russell 3000® Index

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a final list of additions accessed on June 19.

Yahoo | June 22, 2020

Dosing underway in mid-stage study of Immunic's IMU-838 in COVID-19

Immunic ([[IMUX]] -1.6%) announces the start of dosing in a Phase 2 clinical trial, CALVID-1, evaluating IMU-838 plus standard-of-care treatment in COVID-19 patients. Topline data should be available later this year.The company says IMU-838 is an orally available, next-generation immune modulator that dampens the immune response by inhibiting an enzyme called dihydroorotate...

Seeking Alpha | June 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first patients in its phase 2, CALVID-1 clinical trial of IMU-838, the company's selective oral DHODH inhibitor, in coronavirus disease 2019 (COVID-19), at several sites in different European countries. Patients will be enrolled at 10 to 35 centers in Germany, the United States and a half dozen European countries.

Yahoo | June 15, 2020

Why Immunic (IMUX) Stock Might be a Great Pick

Immunic (IMUX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | June 11, 2020

Immunic prices equity offering at $11.40

Immunic (IMUX) has priced its public offering of ~2.175M common shares at $11.40/share, for expected gross proceeds of ~$25M.Roth Capital Partners and Ladenburg Thalmann acted as placement agents.Closing date is June 12.Previously: Immunic to offer common stock, shares extend decline (June 9)...

Seeking Alpha | June 10, 2020

Immunic to offer common stock, shares extend decline

Immunic (IMUX) announced it is commencing an offering of common stock, with the intention to use proceeds to fund development of IMU-838, IMU-935 and IMU-856.Additional proceeds will fund general purposes and the investigation of IMU-838 as a treatment for COVID-19.Shares are lower in after-hours trading. Shares initially rose in the early...

Seeking Alpha | June 10, 2020

P/E Ratio Insights for Immunic

In the current market session, Immunic Inc. (NASDAQ: IMUX) is trading at $12.08, after a 5.63% drop. However, over the past month, the stock increased by 18.66%, and in the past year, by 28.78%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 36.59%.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate marke...

Yahoo | June 10, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6984 seconds.